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Abstract
MRE11 is a component of the MRE11/RAD50/NBS1 (MRN) complex, whose activity is essential to control faithful DNA
replication and to prevent accumulation of deleterious DNA double-strand breaks. In humans, hypomorphic mutations
in these genes lead to DNA damage response (DDR)-defective and cancer-prone syndromes. Moreover, MRN complex
dysfunction dramatically affects the nervous system, where MRE11 is required to restrain MYCN-dependent replication
stress, during the rapid expansion of progenitor cells. MYCN activation, often due to genetic ampliﬁcation, represents
the driving oncogenic event for a number of human tumors, conferring bad prognosis and predicting very poor
responses even to the most aggressive therapeutic protocols. This is prototypically exempliﬁed by neuroblastoma,
where MYCN ampliﬁcation occurs in about 25% of the cases. Intriguingly, MRE11 is highly expressed and predicts bad
prognosis in MYCN-ampliﬁed neuroblastoma. Due to the lack of direct means to target MYCN, we explored the
possibility to trigger intolerable levels of replication stress-dependent DNA damage, by inhibiting MRE11 in MYCN-
ampliﬁed preclinical models. Indeed, either MRE11 knockdown or its pharmacological inhibitor mirin induce
accumulation of replication stress and DNA damage biomarkers in MYCN-ampliﬁed cells. The consequent DDR recruits
p53 and promotes a p53-dependent cell death, as indicated by p53 loss- and gain-of-function experiments.
Encapsulation of mirin in nanoparticles allowed its use on MYCN-ampliﬁed neuroblastoma xenografts in vivo, which
resulted in a sharp impairment of tumor growth, associated with DDR activation, p53 accumulation, and cell death.
Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-ampliﬁed and p53 wild-
type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to
tackle MYCN-driven tumors.
Introduction
MRE11 is a component of the MRE11/RAD50/NBS1
(MRN) complex, which has essential roles in detecting
and repairing DNA double-strand breaks (DSBs) and
activation of the DNA damage response (DDR) via
ATM1,2. Within the complex, the NBS1 and RAD50
moieties mediate nuclear localization and interactions
with DNA and protein partners. MRE11 is essential to
stabilize the complex allowing its accumulation, and to
provide the nuclease activities required for the resection
of the broken DNA ends3,4.
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Hypomorphic MRE11 mutations are responsible for
the inherited Ataxia-Telangiectasia-like disorder
(ATLD), which shares cellular and clinical phenotypes
(including immunodeﬁciency, sterility, and radio-
sensitivity) with Ataxia Telangiectasia (A-T) and Nij-
megen breakage syndrome (NBS), caused by mutations
in the ATM and NBS1 genes, respectively5,6. Complete
loss of Mre11, Nbs1, or Rad50 leads to early embryonic
lethality due to severe proliferation defects in vertebrate
cells7–10. Appropriate animal models recapitulate the
main features of human syndromes and support MRN
tumor suppressive function11–13, consistent with the
increased cancer susceptibility observed in MRN-
defective human syndromes.
Similar to other DNA repair proteins, MRE11 also plays
a pivotal role in controlling the integrity of DNA repli-
cation, preventing the deleterious effects of replication
stress (RS)14–17. Indeed, an inefﬁcient response to RS
seems to contribute to the genesis of developmental dis-
orders of the nervous system, in patients and animal
models carrying mutations in MRN genes18,19.
MYCN is a member of the MYC family of transcription
factors, largely expressed in, and required for, nervous
system development20. As an oncogene, it is deregulated
in several neuronal and non-neuronal tumors of child-
hood, including neuroblastoma, medulloblastoma, reti-
noblastoma, astrocytoma, rhabdomyosarcoma, Wilm’s
tumor, and in adulthood tumors, such as non-small cell
lung cancer and breast cancer (http://www.cancerindex.
org/geneweb/MYCN.htm). At least in neuroblastoma,
where patients are typically stratiﬁed into risk groups
based on multiple parameters, MYCN ampliﬁcation
(MNA) represents the most relevant and independent
negative prognostic factor allowing straightforward
patient classiﬁcation into the high-risk group21–23.
Despite intense multimodal treatment, MNA neuro-
blastoma patients often relapse and succumb to their
disease22, which underscores the need for more effective
therapeutic approaches for these children.
MYC proteins promote RS, DNA damage, and DDR by
several mechanisms24–31. Increased levels of RS have
been clearly detected in primary MNA tumors as com-
pared to MYCN single copy (MNSC) samples31. More-
over, “DNA repair” is among the most signiﬁcantly
deregulated gene ontology groups in neuroblastomas
sharing a MYCN signature32. Overall, these data suggest
that coping with RS and DNA damage is cogent in these
tumors and they are consistent with the knowledge that
DDR proteins can be recruited by oncogenes to dampen
oncogene-dependent RS, eventually favoring cancer cell
survival33–36.
We recently showed the MRE11, RAD50, and NBS1 are
transcriptionally regulated by MYCN in order to prevent
the accumulation of RS-dependent DNA damage during
MYCN-driven expansion of cerebellar granule progenitor
cells26. Whether the MRN complex is essential to prevent
the deleterious effects of MYCN-dependent RS also in
cancer cells was poorly investigated, so far.
Here, we explored the involvement of MRE11 in neu-
roblastoma as a model for MYCN-driven tumors and
addressed the possibility to target the MRN complex to
trigger intolerable levels of RS-dependent DNA damage in
MNA/high-risk tumors.
Results
MRE11 is overexpressed in MNA neuroblastoma and is
essential for MYCN-dependent proliferation
By interrogating multiple neuroblastoma gene expres-
sion datasets on the R2-Genomics platform (http://r2.
amc.nl), we noticed that very high MRE11 expression was
associated with reduced overall survival in primary human
neuroblastoma (Fig. 1a and S1). Consistently, MRE11
mRNA expression was signiﬁcantly higher in worst
prognosis cases characterized by MYCN-ampliﬁed
(MNA) compared to MNSC neuroblastoma tumors 1
(Fig. 1b). This was further conﬁrmed in neuroblastoma
cell lines, at the RNA and protein levels (Fig. 1c). Notably,
a very low MRE11 expression was instead associated with
poor survival and high-risk and stage, in the MNSC
subgroup (Fig. S2A–D). While the latest observation is
consistent with the expected tumor suppressive role of
MRE11, its high expression observed in bad prognosis and
MNA neuroblastoma suggests it might be required for
tumor growth, in this subset. To test the functional role of
MRE11 in neuroblastoma we knocked it down by shRNAi
in the MYCN-repressible SHEP Tet21/N cell line37
(Fig. 1d), where we previously demonstrated MYCN
transcriptionally regulates MRN complex expression26.
Interestingly, this resulted in impaired proliferation and
colony-forming ability in MYCN-overexpressing (hence-
forth MYCN+) cells but not in MYCN repressed (hen-
ceforth MYCN−) cells (Fig. 1e, f).
The MRE11 inhibitor mirin impairs proliferation/survival in
MNA neuroblastoma cells
To further explore whether MRE11 might be required
for the growth of MYCN-driven tumors, we studied the
effects of mirin, an extensively validated pharmacological
inhibitor of MRE11 exonuclease activity26,38,39, by the
MTS assay. MNSC neuroblastoma cells, a number of
human non-neuroblastic cancer cell lines, and NIH3T3
cells showed essentially no or very modest inhibitory
response to mirin up to 100 μM concentration (Fig. 2a
and Table 1). In some instances, lower mirin
[1] Data refer to the GSE62564 dataset (498 neuroblastoma samples). Although
not reported here, similar results can also be obtained by interrogating
GSE45547 and GSE3960 datasets (649 and 101 neuroblastoma samples,
respectively).
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concentrations (20–40 μM) even resulted in increased
MTS assay values in MNSC models (i.e. SK-N-SH, A549).
In sharp contrast, all MNA neuroblastoma cell lines
showed a strong reduction in proliferation already at
40 μM concentration (Fig. 2a). Overall, mirin IC50 ran-
ged between 22.81 and 48.16 μM, for MNA cell
lines, and between 90 to 472 μM in all the others
(Table 1). Importantly, mirin reduced cell viability and
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colony-forming ability more efﬁciently in MYCN+com-
pared to MYCN− cells (Fig. 2b, c).
Overall, these data indicate that MRE11 is essential for
proliferation and/or survival in MYCN-driven tumor cells.
Mirin induces DNA damage and cell death in MNA cells
The MRN complex is involved in multiple DNA repair
pathways, including suppression of replication-associated
DNA DSBs, most likely by preventing fork reversal and/or
facilitating the restart of stalled replication forks14–17.
Moreover, the MRN complex prevents the accumulation
of DNA damages due to MYCN-dependent RS26. Con-
sistently, mirin induced accumulation of 53BP1 nuclear
bodies, a known marker of replication-associated DNA
damage40, and DNA DSBs, in MNA but not MNSC cells
(Fig. 3a, b; S3A, B). Furthermore, it induced H2AX and
p53 phosphorylation in all MNA but not in MNSC cells
(Fig. 3c), indicating the activation of a DDR. Early accu-
mulation of DNA damage and DDR ended up in apoptotic
cell death in MNA but not MNSC cells, as indicated by
the trypan blue exclusion assay, expression of the cleaved
(see ﬁgure on previous page)
Fig. 1 MRE11 expression correlates with poor prognosis and MYCN status in neuroblastoma patients and its depletion affects MYCN-
dependent proliferation/survival in vitro. a Kaplan–Meier curves reporting patients’ overall survival probability with respect to MRE11 expression.
Scan-modus was used for cut-off determination with a minimum group size of 8 to determine the best p-values in a log-rank test (high and low
expression as deﬁned in Figure S1). p-Value was adjusted using Bonferroni correction test for multiple testing. b Box plot of MRE11 expression relative
to MYCN status. The best p-value was calculated using R2-Genomics analysis and visualization platform by the Student’s t-test. ***p < 0.001. c MRE11
mRNA and protein expression as measured by real-time Q-PCR (upper panel) and western blot (WB) analysis (bottom panel) in MNA (LAN5, IMR32,
Kelly) and MNSC (SHEP, GIMEN, SK-N-SH) cell lines. mRNA expression was normalized on GAPDH levels. WBs were probed with β-actin as a loading
control. d–f MYCN+ and MYCN− SHEP Tet21/N cells were subjected to MRE11 knockdown by shRNA interference (MRE11i) and to a short round of
puromycin selection. No-target shRNA interference (CTRi) was used as control. Cells were analyzed for MRE11 and β-actin protein expression (d) and
used for cell proliferation assays (e) (data represent mean ± SD of three independent experiments) and colony formation assays (f) (average data
obtained by three independent experiments are expressed as percentage compared to CTRi-treated controls ± SD). p was calculated by the Student’s
t-test. ***p < 0.001
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Table 1 Mirin IC50 in a panel of neuroblastoma and non-
neuroblastoma cell lines
Cell line IC50 (μM)
IMR32 48.16
KELLY 15.87
LAN5 22.81
SK-N-SH 128.3
GIMEN 89.95
HEK-293T 142.03
NIH3T3 472.41
A549 122.93
HepG2 92.23
Daoy 105.65
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forms of PARP1 and Caspase-3 and TUNEL staining
(Fig. 3c, d). Similar to mirin treatment, also MRE11
depletion by RNAi induced H2AX and p53 phosphor-
ylation and cell death, in MYCN+ cells (Fig. 4a). More-
over, an incomplete MRE11 knockdown reduced mirin-
dependent p53 phosphorylation and accumulation and
impaired mirin-induced cell death (Fig. 4b), supporting an
“on target” activity of mirin.
Together with previously published data41, these
observations suggest that MRE11 may be required to
restrain the accumulation of MYCN-induced and
replication-dependent DNA damage also in cancer cells.
Mirin induces a p53-dependent cell death in MNA cells
Of interest, mirin-dependent DDR activation was
associated with an early and time-dependent
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accumulation of serine 15-phosphorylated p53 and with
the early activation of pro-apoptotic p53 targets, like DR5
and BAX, in MNA cells (Fig. 5a, b), suggesting that mirin-
induced cell death might depend on p53 activity. Con-
sistently, mirin was unable to induce cell death in the p53-
mutant SK-N-BE and in the p53-null LAN1 MNA cell
lines (Fig. 5c, d). Moreover, exogenous p53 expression
restored mirin-induced apoptotic cell death in
LAN1 cells, whereas p53 depletion by shRNAi strongly
reduced the apoptotic response to mirin, in LAN5 cells
(Fig. 5e, f). Therefore, MRE11 inhibition by mirin is
responsible for the DNA damage- and p53-dependent
death, selectively occurring in MNA neuroblastoma
cells.
Mirin encapsulation in biocompatible polymeric
nanocarriers
Due to its essential role in limiting the deleterious effect
of RS in MYCN-driven cancer cells, MRE11 might
represent a novel therapeutic target for MYCN-driven
tumors. So far, mirin (and its structural derivatives39) is
the unique pharmacological inhibitor of MRE11 and,
unfortunately, is rather insoluble in aqueous, alcoholic, or
oleic media, which strongly limits its use in vivo. To
overcome this limitation and to facilitate mirin delivery
into neuroblastoma xenografts in mice, we encapsulated
the inhibitor in nanoparticles made of the copolymer poly
(lactic-co-glycolic)-co-polyethylene glycol (PLGA-b-PEG)
(Fig. S4A). This copolymer is biocompatible, biodegrad-
able, and approved by the Food and Drug Administration
and it has been exploited to create water-dispersible
polymeric nanoparticles (PNPs), which can entrap, pro-
tect, and deliver lipophilic drugs within the body42,43. By
using the nanoprecipitation technique44, mirin was efﬁ-
ciently encapsulated in PNPs, which are stable at phy-
siological pH.
Mirin reduces MNA tumor growth and induces DDR and
apoptosis in vivo
First, we demonstrated that encapsulated mirin (mirine)
very efﬁciently induced DNA damage, DDR, and
cell death in LAN5 cells, in vitro (Fig. S4B–D). Then,
we tested it on LAN5 xenografts in nude mice.
Neuroblastoma-xenografted mice were randomized and
injected daily with mirine (50 mg/kg) or empty nano-
particles. With time, we observed a sharp suppression of
tumor growth in mirine-treated mice compared to con-
trols (Fig. 6a–c). At the hystopathological level, mirine
caused the appearance of hypocellular tumor areas with
nests of neoplastic cells scattered in a desmoplastic
stroma reaction, in which the occurrence of apoptosis was
promptly detected by TUNEL staining (Fig. 6d). More-
over, mirin-induced DDR markers and p53 accumulation
were detected in mirin-treated samples (Fig. 6d, e). These
results indicate that MRE11 inhibition by mirin efﬁciently
restrains tumor growth in vivo by inducing DDR and
apoptosis.
Discussion
More effective and less toxic therapeutic approaches are
urgently needed to overcome the poor prognosis of
MYCN-driven tumors, such as high-risk/MNA neuro-
blastomas. Although inhibiting MYC functions proved to
be an efﬁcient anticancer strategy in preclinical models45,
direct MYCN targeting in clinical settings has not been
achieved, yet. Therefore, looking for MYCN-associated
vulnerabilities might provide alternative strategies for the
treatment of MYCN-driven tumors. Here, we have shown
that targeting MRE11 leads to RS-dependent DNA
damage accumulation, DDR, and p53-dependent cell
death in MNA preclinical tumor models (Fig. 7), in vitro
and in vivo.
Extensive literature supports that MYC oncogenes are
strong inducers of RS24,29,34 and there is reason to believe
that an appropriate control of RS needs to be enforced in
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cells proliferating under MYC pressure26,36. Indeed, we
have recently shown that restraining MYCN-dependent
RS is essential for cell proliferation and survival in the
physiological context of MYCN-dependent expansion of
cerebellar granule progenitor cells. To this end, MYCN
transcriptionally controls the expression of the three
components of the MRN complex to keep RS in-check
during postnatal cerebellar development41. Since we
noticed that high MRE11 expression occurs in MNA
neuroblastoma, we speculated that MRE11 function
might be required to control MYCN-associated RS and
DNA damage, in this tumor subset. Consistently, its
genetic or pharmacological inhibition led to accumulation
of RS and DDR markers and caused cell death, speciﬁcally
in MNA neuroblastoma.
Spehalski et al.46 reported that Mre11 deﬁciency pre-
vented tumorigenesis in mouse p53−/− B-cell lymphoma
models associated with oncogenic translocations invol-
ving Myc genes, indicating that MRE11 (and by extension
the MRN complex) cannot be considered a standard
tumor suppressor since its activity is required for cancer
development. In line with this, we have now demonstrated
that MRE11 is also required for an efﬁcient RS control
and for the survival of preclinical models of established
MYCN-driven human cancer. Consistently, our data also
add up that high MRE11 expression predicts very poor
prognosis in high-risk neuroblastoma and that
nanoparticle-mediated delivery of its pharmacological
inhibitor mirin strongly impairs the growth of MNA
tumor xenografts. Therefore, by addressing similar but
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not identical issues in different tumor models, all together
these data strongly support the idea that targeting the
MRN complex might represent a good strategy to tackle
MYC(N)-driven tumors.
It has been recently reported that p53 orchestrates DNA
replication restart homeostasis via a transcription- and
apoptosis-independent function, by aiding MRE11
recruitment on stalled replication forks to prevent the
activity of RAD52/Polθ mutagenic pathways47. While it is
likely that MRE11 recruitment onto “stressed” forks is
strictly connected to its tumor survival functions, data
from Spehalski et al.46 imply that p53 is dispensable to
this end, since they unveiled MRE11 oncogenic activity in
p53−/− B-cell lymphomas. Further studies will be deﬁ-
nitely required to better deﬁne the complex relationships
between p53 and the MRN complex at the replication
forks, in normal and cancer cells. Nonetheless, our data
clearly indicate that p53 is required to enhance cell death
upon MRE11 inhibition, in MNA neuroblastoma, sug-
gesting that preservation of p53 integral function is
important in this context. Of relevance, p53 mutations
rarely occur in primary neuroblastomas and in other
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MYCN-driven tumors48,49, supporting the possibility to
enforce this therapeutic strategy in this tumor subset.
A large fraction of aggressive and MYCN-driven neu-
roblastomas is associated with a speciﬁc signature
impinging on DNA replication, DNA repair, and cell cycle
regulators32,50, suggesting that this gene expression pro-
gram, which includes transcriptional regulation of MRE11
(ref.26), might be pivotal to increase cell tolerance to RS
and its related DNA damages in MYCN-driven tumors.
Based on the data presented here, these observations
more broadly suggest that a number of potential candi-
dates could be targeted for therapeutic purposes in
MYCN-driven tumors. Moreover, this strategy could be
quickly translated into clinical trials, due to the availability
of approved drugs against well-known RS/DNA damage
processing factors. In example, MYCN-driven neuro-
blastoma consistently showed a notable sensitivity to
CHK1 and/or PARP inhibitors, in vitro and in xenograft
models51,52. In addition, simultaneous targeting of DNA
repair and cell cycle regulators seems to be most effective
in killing MYCN-driven tumors by raising RS and DNA
damage over the threshold for survival51. Nonetheless, the
best candidates belonging to RS, DDR, or DNA repair
pathways to be tackled in order to exploit MYCN-
associated vulnerabilities are far from being fully estab-
lished. Rather, there is room to believe that inhibiting
distinct targets might differentially impact on tumor cell
survival, in different molecular contexts. Indeed, while we
described efﬁcient killing of wild-type p53/MYCN-driven
tumors by MRE11 inhibition, ATR-CHK1 signaling seems
to be especially essential for MYC-driven tumors in a p53-
defective backgrounds34,35, which rarely occurs in MNA
neuroblastoma.
Remarkably, decreasing MRE11 expression may even-
tually favor proliferation and colony-forming capabilities
in non-MNA cells (see Fig. 1e, f), which is consistent with
very low MRE11 expression being associated with poor
prognosis, in primary MNSC neuroblastomas. While
these data match the renowned tumor suppressive func-
tion of MRE11, they also highlight that its inhibition
might be detrimental in non-MYCN-driven tumors.
These ﬁndings suggest the need for an appropriate tai-
loring of MRE11 inhibition and indicate the use of MNA
and p53 status as potential selective biomarkers.
In conclusion, our work indicates that MRE11 inhibi-
tion might be an effective strategy to treat MYCN-driven
tumors encouraging the search for new pharmacological
inhibitors of the MRN complex.
Materials and methods
Public dataset gene expression analysis
R2-Genomics analysis and visualization platform
(http://r2.amc.nl) was utilized to study gene expression of
MRE11 in the SEQC-498-RPM dataset. Data were ana-
lyzed and downloaded from the website and formatted for
publication.
Cell lines and culture conditions
GIMEN were acquired from Banca Biologica and Cell
Factory (Genoa, Italy; www.iclc.it); IMR32 and SK-N-BE
from European Collection of Cell Cultures (Porton Down,
UK; www.ecacc.org.uk); and LAN5 and Kelly from
Deutsche Sammlung von Mikroorganismen und Zellk-
ulturen (Braunschweig, Germany; www.dsmz.de). LAN1
and SK-N-SH cells were a kind gift of Dr. Nicole Gross
(Department of Pediatrics, University Hospital, Lausanne,
Switzerland) and Dr. Carol J. Thiele (NCI, Bethesda, MD),
respectively. All these cell lines were validated by short
tandem repeat DNA STR analysis (LGC Standards, Ted-
dington, Middlesex, UK). SHEP Tet21/N cell line,
received from Dr. Schwab, DKFZ, Heidelberg, Germany,
is a MNSC neuroblastoma cell line in which exogenous
MYCN expression is under the control of a tetracycline
responsive promoter (Tet-off system)37. The cells were
cultured and validated for MYCN induction as reported37.
MYCN
DNA replication / 
proliferation
Replication 
stress
Cancer cell
survival
DNA damage
MRE11
Mirin
Cancer
cell death
p53 activation
Cancer
cell death
p53 activation
Fig. 7 Schematic representation of the effects of MRE11
inhibition on MYCN-dependent tumors. While promoting an
increased proliferation rate, MYCN overexpression also causes high
levels of RS, which in turn would be responsible for the accumulation
of DNA damage and cell death, if improperly controlled. However,
MYCN regulates the expression of MRE11 to keep the deleterious
effects of RS in check, thus allowing survival and proliferation of
MYCN-driven tumor cells. Under these conditions, MRE11 inhibition
leads to accumulation of RS-dependent DNA damage, DDR activation,
and p53-dependent cell death
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HEK-293T, NIH3T3, HepG2, DAOY, and A549 cells were
obtained from the repository of our Department. All cells
were grown in standard conditions as reported53 and
tested for mycoplasma infection using EZ-PCR Myco-
plasma Test Kit (Biological Industries, Cromwell, CT,
USA).
Unless otherwise speciﬁed, cell lines were exposed to the
MRE11 inhibitor mirin (Sigma Aldrich, St. Louis, MO,
USA) at 40 μM concentration for either 15 (western blot
analysis) or 48 h (trypan blue exclusion test and MTS assay).
Transfection and lentivirus infection
MRE11 interference was performed using either a
PLKO.1 plasmid expressing a speciﬁc shRNAi
(CCGGACGGGAACGTCTGGGTAATTCCTCGAGGA
ATTACCCAGACGTTCCCGTTTTTTG; Sigma Aldrich)
or by stealth RNAi (ACAUGUUGGUUUGCUGCGUAU
UAAA; Invitrogen, Carlsbad, CA, USA). The p53 con-
struct (pCAGp53) was previously described27. Plasmid
and RNAi were transfected by Lipo2000 Transfection
Reagent (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
according to the manufacturer’s instructions. p53
knockdown was achieved by infecting LAN5 cells with
lentiviral transduction particles (pLV-WPXL-shp53 and
pLV-WPXL-shCTR) as previously described54.
RNA preparation and Q-PCR
mRNA was extracted using TRIzol reagent (Invitrogen)
and quantitative reverse transcription-PCR was per-
formed as previously described55,56. Q-PCR primer
sequences are available as supplementary information.
Western blot
Total protein extraction and western blot protocols
have been previously described56. Immunoreactive bands
were visualized by enhanced chemoluminescence
(Advansta Inc., Menlo Park, CA, USA). Antibodies were
as follows: MRE11 (12D7) ab214 (Abcam, Cambridge,
UK); PARP 85 fragment #G7341 (Promega Corporation,
Medison, WI, USA); Caspase-3 #9662, phospho-histone
H2AX (ser 139) #2577 and phospho-p53 (Ser 15) #9284
(Cell Signaling Technology, Danvers, MA), USA; p53
(DO-1) #SC-126 and β-actin (I–19) #SC-1616 (Santa Cruz
Biotechnology, INC, Dallas, TX, USA).
Cell proliferation, cell death analysis, colony formation
assay, and comet assay
MTS assay was performed using the MTS Cell Titer 96
aqueous one solution reagent (Promega Corporation)
according to the manufacturer’s protocol and absorbance
(450 nm) was recorded using a Glomax Multidetection
Luminometer (Promega Corporation). Cell proliferation,
cell death, and colony formation assays were performed
as described27,57. For TUNEL staining, ﬁxed cells were
labeled using the in situ Cell Death Detection Kit (Roche
Diagnostics, Indianapolis, IN, USA). At least 200 cells/
sample were counted. Neutral comet assay was conducted
as described26.
Immunoﬂuorescence assay and immunohistochemistry
Cells were ﬁxed in 4% formaldehyde/phosphate-buf-
fered saline (PBS) for 10 min at RT, permeabilized in 0.5%
Triton X-100, blocked in 3% goat serum, in PBS and
incubated with anti-53BP1 antibody (NB100-304, Novus
Biological, LLC) for 1 h at room temperature and revealed
with AlexaFluor secondary antibody (Life Technologies).
Images were acquired on a LEICA DM 2500 microscope.
Formalin-ﬁxed and parafﬁn-embedded tissue sections
(4 μm thickness) were probed with phospho-histone
H2AX (Ser 139) (20E3; Cell Signaling Technology),
phospho-p53 (Ser 15) (#9284; Cell Signaling Technology)
speciﬁc antibodies, according to the manufacturer's
instruction of mouse2mouse HRP ready to use kit
(MTM001, ScyTek Laboratories, Logan, UT, USA). Ima-
ges were captured using the microscope Leica DM1000.
Synthesis of mirine
Poly (D,L-lactide-co-glycolide) (50/50) with the car-
boxylic acid end group (PLGA-COOH, inherent viscosity
0.12 dL/g, MW ~7 kDa) was purchased from Lakeshore
Biomaterials (Birmingham, AL, USA). Polyethylene glycol
with amino and carboxylic acid end groups (NH2-PEG-
COOH, MW ~3 kDa) was purchased from Rapp Polymere
GmbH (Tübingen, Germany). All aqueous solutions were
prepared with deionized water obtained using an ultra-
ﬁltration system (Milli-Q, Millipore) with a measured
resistivity above 18MΩ/cm.
Two hundred and ﬁfty milligrams of PLGA-b-PEG-
COOH (10 kDa, 0.025mmol) were prepared as previously
described58 and 50mg of mirin (0.23mmol) were dissolved
in 25mL of DMSO. The organic phase was mixed to
250mL of ultrapure water under vigorous stirring for 30
min, maintaining water/organic ratio 10/1 with a constant
removal of the resulting solution. The mixture was subse-
quently puriﬁed and concentrated using centrifugal ﬁlter
devices (Amicon Ultra, Ultracell membrane with 100,000
NMWL; Millipore, Billerica, MA, USA) to a ﬁnal volume of
20mL, passed through a ﬁlter SterivexTM-GP 0.22 μm of
polyether sulfone (Millipore, USA) and stored at 4 °C. The
same procedure was exploited to obtain empty nano-
particles. DLS measurements were performed on a Malvern
Zetasizernano-S working with a 532 nm laser beam.
ζ potential measurements were conducted in DTS1060C-
Clear disposable zeta cells at 25 °C. To asses mirin con-
centration, a sample aliquot (50 µL) was diluted with 3mL
of DMSO and analyzed by UV–Vis (λmax= 453 nm) after
sonication (15min) in order to destroy the nanoparticles
and re-disperse the drug.
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Xenograft generation and analysis
LAN5 cells (2.5 × 106 cells/ﬂank) were suspended in an
equal volume of medium and Matrigel (BD Biosciences,
Heidelberg, Germany) and injected at the posterior ﬂank
of female BALB/c nude mice (nu/nu) (Charles River
Laboratories, Lecco, Italy). When tumors reached a
median size of 260 mm3, animals were randomly divided
into two groups (n= 5) and locally injected with vehicle
or mirine for 11days. Tumor growth was monitored by
caliper. Tumor volumes change was calculated by the
formula length × width × 0.5 × (length+width). Animal
experiment was approved by local ethics authorities
(protocol no. 379/2016-PR) and was performed according
to the guidelines for animal care.
Statistical analysis
Statistical analysis was performed by a standard
two-tailed Student’s t-test or ANOVA test using
GraphPRISM6 software, as indicated. For all tests a
p-value <0.05 was considered to indicate statistical sig-
niﬁcant differences. The software GraphPRISM6 was used
to determine IC50. Error bar represent standard deviation
(SD) or standard errors (SEM) as indicated.
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